The Schall Law Firm, a national shareholder rights litigation firm based in Los Angeles, has announced a class action lawsuit against Biohaven Ltd. (NYSE: BHVN). The lawsuit alleges that Biohaven violated federal securities laws.
The firm claims that Biohaven misled investors regarding the regulatory prospects of its drug candidate, troriluzole, a treatment for SCA. Additionally, the firm asserts that the company overstated the efficacy of BHV-7000 as a treatment for bipolar disorder.
These allegedly false and misleading statements were made between March 24, 2023, and May 14, 2025. When the market learned of the alleged inaccuracies, the firm contends, investors experienced financial losses.
Schall Law Firm encourages investors who purchased Biohaven securities during this period to contact them before September 12, 2025. The firm is offering a free consultation to discuss their legal rights.
The lawsuit is still in its early stages. No class certification has occurred yet. Investors are not automatically represented by an attorney unless and until the class is certified. Those who choose not to participate can still remain as absent class members.
The Schall Law Firm specializes in securities class action lawsuits and shareholder rights litigation. They represent investors globally. Interested parties can contact Brian Schall at 310-301-3335 or via email at bschall@schallfirm.com. The firm’s address is 2049 Century Park East, Suite 2460, Los Angeles, CA 90067. Their website also provides additional information.
It is important to note that this press release may be considered attorney advertising under certain jurisdictions. The information provided is for informational purposes only and does not constitute legal advice.
Related
